Egypt’s Eipico starts manufacturing Covid-19 drug Epifluver

By Amwal Al Ghad English On Jul 28, 2020

Egyptian International Pharmaceutical Industries Co. (Eipico) said on Tuesday it has started manufacturing the Covid-19 drug (Epifluver – Favipiravir 200 mg).

Eipico started manufacturing the medicine, which has been used in Russia and China in treating Covid-19 patients, after obtaining the Egyptian Drug Authority’s (EDA) approval.

During the January-March period, the company posted net profits worth 189.1 million Egyptian pounds ($11.8 million) from 218.31 million pounds during the same period of 2019.

The company also achieved standalone profits estimated at 165.21 million pounds during the first quarter of the current financial year versus 203.31 million pounds during the same period last year.

Coronavirus COVID-19 Egyptian Drug Authority (EDA)Egyptian International Pharmaceutical Industries Co. (EIPICO)Epifluver – Favipiravir 200 mg favipiravir